Benchmark processes first batch of commercial-scale antigen
Late in October Benchmark announced that its first commercial-scale batch of antigen has been processed at its facility in Braintree, UK.
The antigen will be used in a number of new aquaculture vaccines in Benchmark’s product pipeline.
Work on the final validation of the $22 million biotechnology building, to ensure compliance with EU Good Manufacturing Practices (GMP) is underway. Once fully licensed the increased capacity will allow Benchmark to expand the number and range of vaccines it produces.
According to Benchmark, the 2,500-square-metre facility is set to be one of the most capable EU GMP antigen production facilities in Europe.
Flood-damaged West Virginia hatchery expects full recovery in 2019West Virginia’s White Sulphur Springs National Fish Hatchery expects to…
Fish InternationalSun Feb 25, 2018
China Fish 2018Mon Feb 26, 2018
19th world congress on analytical & bioanalytical techniquesWed Sep 19, 2018 @11:00AM - 05:00PM